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The high fibreoptic score using the i-gel was especially note-
worthy. In only 2% of the cases, it was not possible to see the
vocal cords.2 In our hospital, we have a considerable number
of difficult airways due to malignancies in the larynx/
pharynx. Although awake fibreoptic intubation remains the
gold standard in manydifficult airway patients, we increasingly
use the i-gel for ventilation in patients with an interdental gap
of ≥3 cm. Once the patient’s lungs are ventilated, we intubate
the trachea using aflexible scope through the i-gel. When lubri-
cated properly, an oral tracheal tube (size 7.0) can be effortless-
ly pushed along the flexible scope through the i-gel in between
the vocal cords. Correct positioning is easily achievable using
the scope. If desired, the i-gel can be removed while the tra-
cheal tube is held in the correct place using surgical forceps.
This method appears to be so successful that it is increasingly
being used in our department in the case of an unexpected dif-
ficult airway. The main requirements for this technique are the
use of an i-gel 4 (or 5) and an interdental gap of at least 3 cm. By
using the i-gel for ventilation before tracheal intubation, one
limits the number of manipulations in the larynx, thus reducing
the development of swelling, hypersalivation, and potential
bleeding.
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Reply from the authors
Editor—We read with interest the letter by Dr Sramek and
Dr Keijzer. We are thankful for this valuable contribution.
Dr Sramek correctly points out that the i-gel (and many other
supraglottic airway devices) provide an excellent back-up
device to fibreoptically intubate a patient with a difficult
airway. It is especially noteworthy that an awake technique
should remain the gold standard in expected difficult airway
management. As we have shown in our study cited by
Dr Sramek, there is an overlap of risk factors predicting
difficulties with i-gel ventilation and also difficulties with face-
mask ventilation.1 Therefore, unfortunately, when both stand-
ard laryngoscopy and face-mask ventilation fail (cannot intub-
ate, cannot ventilate), there is an increased risk for difficulties
with supraglottic airway device insertion and ventilation as well.
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In science, all facts, no matter how trivial or
banal, enjoy democratic equality
Editor—In the alluring and rapidly expanding field of develop-
mental anaesthetic neurotoxicity, facts have been accumulat-
ing at a tremendous rate. The overview of recent work in this
area provided by Sanders and colleagues,1 covering both
laboratory and clinical studies, is therefore a welcome addition
to the literature.
However, rather than providing a critical and unbiased
evaluation of the all-important hypothesis—that a clinically
relevant neurotoxic effect of anaesthetics exists—like most
other investigators in the field, the authors approach the
topic with an implicit assumption that any demonstrable
effect must be meaningful. Indeed, already in the introduction,
the burden of proof is squarely placed on those questioning the
existence of the condition under study when the authors write,
‘these accumulating clinical data cannot exclude a clinically
important effect . . . on cognition in later life’. In science,
proof of non-existence of anything is notoriously difficult, if
not outright impossible. Therefore, one must consider
whether current knowledge justifies treating the clinical rele-
vance of anaesthetic neurotoxicity as an established paradigm
(and hence the demand to demonstrate its non-existence) as
opposed to a hypothesis still awaiting proof.
With respect to rodent data, which constitute the bulk of
available information, it is worth pointing out that most experi-
ments were conducted using inbred strains. Inbreeding, by
reducing genetic variability, may create both susceptibility to
injury and limit compensatory potential, adding to the prob-
lems of extrapolating from rodent data to the human condi-
tion. Therefore, the authors appropriately highlight the
importance of studies in animals other than rodents. On this
background, the lenience with which the methodological defi-
ciencies of the piglet studies are downplayed is striking: the lack
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